Table 3.
Proportion of patients with HZ with PHN, at least one HZ complication other than PHN, or vascular complications as assessed within 90 days of HZ onset, HES-CPRD, 2000–2011
| Type of complications | IC cohort (N=21 146) | IC-free cohort (N=18 583) | ||
| n (%) | 95% CI | n (%) | 95% CI | |
| PHN | 2253 (10.65) | 10.24 to 11.08 | 1690 (9.09) | 8.68 to 9.52 |
| HZ complications other than PHN (overall) | 623 (2.95) | 2.72 to 3.18 | 436 (2.35) | 2.13 to 2.57 |
| Ocular | 411 (1.94) | 1.76 to 2.14 | 299 (1.61) | 1.43 to 1.8 |
| Neurological other than PHN | 137 (0.65) | 0.54 to 0.77 | 85 (0.46) | 0.37 to 0.57 |
| Disseminated | 12 (0.06) | 0.03 to 0.1 | 1 (0.01) | 0 to 0.03 |
| Other complications | 69 (0.33) | 0.25 to 0.41 | 54 (0.29) | 0.22 to 0.38 |
| Vascular complications | ||||
| Stroke | 88 (0.42) | 0.33 to 0.51 | 105 (0.57) | 0.46 to 0.68 |
| Transient ischaemic attack | 52 (0.25) | 0.18 to 0.32 | 30 (0.16) | 0.11 to 0.23 |
| Optic neuritis, vascular retinitis | 9 (0.04) | 0.02 to 0.08 | 5 (0.03) | 0.01 to 0.06 |
| Myocardial infarction | 36 (0.17) | 0.12 to 0.24 | 23 (0.12) | 0.08 to 0.19 |
CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; HZ, herpes zoster; IC, immunocompromised; N, Number of patients with HZ; n (%), number (percentage) of the patients with HZ with this complication; PHN, postherpetic neuralgia.